PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis

Journal of Controlled Release

Volumn 154, Issue 3, 2011, Pages 233-240

  Bansal, Ruchi ^a   Post, Eduard ^a   Proost, Johannes H ^a   De Jager Krikken, Alie ^a   Poelstra, Klaas ^a   Prakash, Jai ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Fibrosis; Interferon gamma; PEGylation; Stellate cells

Indexed keywords

ACUTE LIVER INJURY; ANTI-PROLIFERATIVE; APOPTOTIC; CLINICAL USE; CYTOKINES; EXTRACELLULAR MATRICES; FIBROSIS; IMMUNOHISTOCHEMICAL STAINING; IN-VITRO; IN-VIVO; INTERFERON GAMMA; LIVER ACCUMULATION; LIVER FIBROSIS; NITRIC OXIDE RELEASE; PEGYLATION; PHARMACOKINETIC DATA; PHARMACOKINETIC PROFILES; QUANTITATIVE PCR; RENAL CLEARANCE; STELLATE CELLS; THERAPEUTIC APPLICATION; THERAPEUTIC EFFECTS; VIRAL HEPATITIS;

ANTIBIOTICS; CELL CULTURE; DISEASES; ENZYME INHIBITION; GLYCOPROTEINS; MAMMALS; NITRIC OXIDE; POLYMERASE CHAIN REACTION;

PHARMACOKINETICS;

GAMMA INTERFERON; MACROGOL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEGINTERFERON; PEGYLATED GAMMA INTERFERON; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG UPTAKE; LIVER FIBROSIS; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; INTERFERON-GAMMA; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED BALB C; NIH 3T3 CELLS; POLYETHYLENE GLYCOLS;

EID: 80052541057     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.05.027     Document Type: Article

References (34)

1. R. Bataller, and D.A. Brenner Liver fibrosis J. Clin. Investig. 115 2005 209 218 (Pubitemid 40385459)
2. D. Schuppan, and N.H. Afdhal Liver cirrhosis Lancet 371 2008 838 851 (Pubitemid 351323895)
3. S.L. Friedman Stellate cells: a moving target in hepatic fibrogenesis Hepatology 40 2004 1041 1043 (Pubitemid 39425557)
4. S.L. Friedman Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver Physiol. Rev. 88 2008 125 172
5. O.A. Gressner, R. Weiskirchen, and A.M. Gressner Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options Comp. Hepatol. 6 2007 7
6. D.C. Rockey Current and future anti-fibrotic therapies for chronic liver disease Clin. Liver Dis. 12 2008 939 962 xi.
7. E.M. Bonnem, and R.K. Oldham Gamma-interferon: physiology and speculation on its role in medicine J. Biol. Response Mod. 6 1987 275 301 (Pubitemid 18040530)
8. C.H. Miller, S.G. Maher, and H.A. Young Clinical use of interferon-gamma Ann. N. Y. Acad. Sci. 1182 2009 69 79
9. K. Schroder, P.J. Hertzog, T. Ravasi, and D.A. Hume Interferon-gamma: an overview of signals, mechanisms and functions J. Leukoc. Biol. 75 2004 163 189 (Pubitemid 38174573)
10. P.J. Pockros, L. Jeffers, N. Afdhal, Z.D. Goodman, D. Nelson, R.G. Gish, K.R. Reddy, R. Reindollar, M. Rodriguez-Torres, S. Sullivan, L.M. Blatt, and S. Faris-Young Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis Hepatology 45 2007 569 578 (Pubitemid 46450609)
11. I. Rutenfranz, and H. Kirchner Pharmacokinetics of recombinant murine interferon-gamma in mice J. Interferon Res. 8 1988 573 580
12. H.M. Younes, and B.G. Amsden Interferon-gamma therapy: evaluation of routes of administration and delivery systems J. Pharm. Sci. 91 2002 2 17 (Pubitemid 34074463)
13. G.S. Baroni, L. D'Ambrosio, P. Curto, A. Casini, R. Mancini, A.M. Jezequel, and A. Benedetti Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis Hepatology 23 1996 1189 1199 (Pubitemid 26137066)
14. W.I. Jeong, O. Park, S. Radaeva, and B. Gao STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity Hepatology 44 2006 1441 1451 (Pubitemid 44953650)
15. M. Hamidi, A. Zarrin, and M. Foroozesh Novel delivery systems for interferons Crit. Rev. Biotechnol. 27 2007 111 127 (Pubitemid 47396421)
16. G.E. Francis, D. Fisher, C. Delgado, F. Malik, A. Gardiner, and D. Neale PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques Int. J. Hematol. 68 1998 1 18 (Pubitemid 28368166)
17. S. Jevsevar, M. Kunstelj, and V.G. Porekar PEGylation of therapeutic proteins Biotechnol. J. 5 2010 113 128
18. J.S. Kang, P.P. Deluca, and K.C. Lee Emerging PEGylated drugs Expert Opin. Emerg. Drugs 14 2009 363 380
19. F.M. Veronese, and G. Pasut PEGylation, successful approach to drug delivery Drug Discov. Today. 10 2005 1451 1458 (Pubitemid 41483874)
20. T. Poynard, J. McHutchison, M. Manns, C. Trepo, K. Lindsay, Z. Goodman, M.H. Ling, and J. Albrecht Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313 (Pubitemid 34465173)
21. C. Camma, B.D. Di, F. Schepis, E.J. Heathcote, S. Zeuzem, P.J. Pockros, P. Marcellin, L. Balart, A. Alberti, and A. Craxi Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data Hepatology 39 2004 333 342 (Pubitemid 38222174)
22. Y.M. Kim, and K. Son A nitric oxide production bioassay for interferon-gamma J. Immunol. Meth. 198 1996 203 209 (Pubitemid 26378878)
23. M.M. van Beuge, J. Prakash, M. Lacombe, E. Post, C. Reker-Smit, L. Beljaars, and K. Poelstra increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the rho-kinase inhibitor Y27632 Pharm. Res. 2011
24. J. Wu, and P.A. Norton Animal models of liver fibrosis Scand. J. Gastroenterol. 31 1996 1137 1143 (Pubitemid 26403086)
25. A.H. van Boxel-Dezaire, and G.R. Stark Cell type-specific signaling in response to interferon-gamma Curr. Top. Microbiol. Immunol. 316 119-54 2007 119 154
26. C.M. Horvath The Jak-STAT pathway stimulated by interferon gamma Sci. STKE 2004 2004 tr8
27. A. Muhlethaler-Mottet, B.W. Di, L.A. Otten, and B. Mach Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1 Immunity 8 1998 157 166 (Pubitemid 28123743)
28. M.A. Farrar, and R.D. Schreiber The molecular cell biology of interferon-gamma and its receptor Annu. Rev. Immunol. 11 1993 571 611 (Pubitemid 23115018)
29. D. Bouros, K.M. Antoniou, A. Tzouvelekis, and N.M. Siafakas Interferon-gamma 1b for the treatment of idiopathic pulmonary fibrosis Expert. Opin. Biol. Ther. 6 2006 1051 1060 (Pubitemid 44497129)
30. S.D. Oldroyd, G.L. Thomas, G. Gabbiani, and A.M. El Nahas Interferon-gamma inhibits experimental renal fibrosis Kidney Int. 56 1999 2116 2127 (Pubitemid 30004740)
31. J.L. Cleland, and A.J. Jones Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres Pharm. Res. 13 1996 1464 1475 (Pubitemid 26356947)
32. F. Gu, H.M. Younes, A.O. El-Kadi, R.J. Neufeld, and B.G. Amsden Sustained interferon-gamma delivery from a photocrosslinked biodegradable elastomer J. Control. Release 102 2005 607 617 (Pubitemid 40170204)
33. B.M. Brooks, B.F. Flanagan, A.L. Thomas, and J.W. Coleman Penicillin conjugates to interferon-gamma and reduces its activity: a novel drug-cytokine interaction Biochem. Biophys. Res. Commun. 288 2001 1175 1181 (Pubitemid 33131724)
34. B.M. Brooks, A.L. Thomas, and J.W. Coleman Benzylpenicillin differentially conjugates to IFN-gamma, TNF-alpha, IL-1beta, IL-4 and IL-13 but selectively reduces IFN-gamma activity Clin. Exp. Immunol. 131 2003 268 274 (Pubitemid 36205138)